Education
About Us
Working with TipRanks
Follow Us
Veracyte Inc (VCYT)
:VCYT
VCYT Stock Chart & Stats
$36.12
$0.68(1.60%)
At close: 4:00 PM EST
$36.12
$0.68(1.60%)
Day’s Range― - ―
52-Week Range$22.61 - $47.32
Previous CloseN/A
Volume253.49K
Average Volume (3M)783.87K
Market Cap
$2.84B
Enterprise Value$2.41B
Total Cash (Recent Filing)$366.43M
Total Debt (Recent Filing)$40.45M
Price to Earnings (P/E)121.3
Beta1.57
Next Earnings
Mar 02, 2026EPS Estimate
0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding78,671,585
10 Day Avg. Volume707,400
30 Day Avg. Volume783,865
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)2.58
Price to Sales (P/S)6.79
P/FCF Ratio47.47
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue4.87
Enterprise Value/Gross Profit7.14
Enterprise Value/Ebitda51.15
Forecast
1Y Price Target
$42.17Price Target Upside16.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceVeracyte exceeded estimates across all key metrics and increased its guidance range.
Product LaunchesVeracyte is on its way to launching its MRD test and Prosigna LDT in the first half of 2026, creating additional value in shares.
Revenue GrowthManagement raised 2025 revenue guidance and adjusted EBITDA margin guidance.
Bears Say
Market PenetrationHigh market penetration raises questions around sustainability for Veracyte's flagship tests.
Pipeline StrategyIt is unclear to what extent Veracyte's test platform transition strategy and pipeline will drive solid long-term revenue growth and benefit its financial profile.
Reimbursement ChallengesNasal Swab reimbursement is unlikely to fall in place until 2028+ at the earliest in light of the NIGHTINGALE enrollment expected to complete in 3Q25.
Veracyte News
VCYT FAQ
What was Veracyte Inc’s price range in the past 12 months?
Veracyte Inc lowest stock price was $22.61 and its highest was $47.32 in the past 12 months.
What is Veracyte Inc’s market cap?
Veracyte Inc’s market cap is $2.84B.
When is Veracyte Inc’s upcoming earnings report date?
Veracyte Inc’s upcoming earnings report date is Mar 02, 2026 which is in 112 days.
How were Veracyte Inc’s earnings last quarter?
Veracyte Inc released its earnings results on Nov 04, 2025. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.321 by $0.189.
Is Veracyte Inc overvalued?
According to Wall Street analysts Veracyte Inc’s price is currently Undervalued.
Does Veracyte Inc pay dividends?
Veracyte Inc does not currently pay dividends.
What is Veracyte Inc’s EPS estimate?
Veracyte Inc’s EPS estimate is 0.38.
How many shares outstanding does Veracyte Inc have?
Veracyte Inc has 78,671,585 shares outstanding.
What happened to Veracyte Inc’s price movement after its last earnings report?
Veracyte Inc reported an EPS of $0.51 in its last earnings report, beating expectations of $0.321. Following the earnings report the stock price went up 27.464%.
Which hedge fund is a major shareholder of Veracyte Inc?
Currently, no hedge funds are holding shares in VCYT
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.17 (16.75% Upside)
$42.17 (16.75% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 969.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.13%
12-Months-Change
Fundamentals
Return on Equity
2.49%
Trailing 12-Months
Asset Growth
7.28%
Trailing 12-Months
Company Description
Veracyte Inc
Veracyte, Inc. is a genomic diagnostics company that focuses on improving patient outcomes through the development and commercialization of diagnostic tests for patients with cancer and other diseases. The company operates primarily in the healthcare sector, offering innovative solutions that enhance the accuracy of diagnoses and help physicians make informed treatment decisions. Veracyte's core products include its proprietary genomic tests, such as the Afirma Genomic Sequencing Classifier for thyroid cancer and the Percepta Genomic Sequencing Classifier for lung cancer, which are designed to reduce unnecessary surgeries and improve patient management.
VCYT Company Deck
VCYT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Veracyte delivered a strong quarter with record revenue growth and profitability, driven by robust performance from its core testing business, particularly Decipher and Afirma. The company achieved a significant milestone by reaching its adjusted EBITDA margin target ahead of schedule. However, challenges remain in the form of declining biopharmaceutical revenue, competitive pressures from new technologies, and a slight decrease in testing ASP.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$42.17
▲(16.75% Upside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
1.39% Insiders
38.58% Mutual Funds
0.11% Other Institutional Investors
24.27% Public Companies and
Individual Investors